Reflecting on 2025: Year in Review
Looking back on our highlights of 2025, the year has been defined by several notable achievements. In this blog, we have highlighted the top milestones we are most proud of. Throughout it all, our core values—curiosity, fun, and quality—have guided every initiative and experience.
Here are our Top 5 highlights of the year in words and (pictures!):
1. Commercial in EU and UK (CE-marking and MHRA registration)
One of our key milestones this year was achieving CE Marking for VAX-ID, our intradermal drug delivery device. This enables commercial availability across the European market and expands access to our innovative technology. Read more here.
Additionally, VAX-ID was successfully registered with the UK Medicines and Healthcare Products Regulatory Agency (MHRA). Supported by Idevax’s UK Responsible Person, QbD Group, VAX-ID is now approved for the UK market. Read more here.
2. Participation in global conferences
Our team has been actively engaged in leading international industry events, including PharmaPack, Advanced Therapies, SuperNova, the European Lymphatic Symposium, LSX World Congress, Knowledge for Growth, Cancer Vaccines Congress, the BIO Convention, Medica, World Vaccine Congress, Festival of Biologics, Immunity for Health, EADV, and Life Science Baltics.
Importantly, these conferences allowed us to meet industry experts, present our work, host booths, expand our global network, and stay up to date with the latest developments in the field. Check out all our events.
3. New & exciting projects: RABIVA
Idevax is proud to collaborate with Rabian and Artemis Bioservices on RABIVA, an EUROSTARS-funded project focused on advancing innovative and accessible solutions for RNA virus prevention.
RABIVA—the world’s first affordable approach to intradermal rabies vaccination—addresses a disease that is 100% vaccine-preventable yet still causes over 60,000 deaths annually. Indeed, by combining cutting-edge technologies, the project aims to deliver a cost-effective, scalable, and user-friendly vaccination platform for endemic regions and travelers alike. Importantly, the project is supported by the EUROSTARS programme under Horizon Europe, with support VLAIO (Flanders) and RVO (The Netherlands).
Make sure to read the full details here.
4. Growing our team
We significantly expanded our team this year, welcoming new colleagues across key roles including Biomedical Scientist, Human Health Engineer, Business Development Advisor, as well as interns. We are now a strong team of 16 members across multiple locations, staying connected through regular company-wide meetings, as well as team dinners and gatherings. Learn more about our fantastic team.
5. Fresh content and a growing community
We continue to strengthen our digital presence this year by refreshing key sections of our website and adding new content, including several white papers. Among the latest is “Intradermal delivery: a promising method for breast cancer immunotherapy.” Explore our white papers.
Also, our LinkedIn community is also growing steadily. Reaching more than 73,000 impressions and surpassed 2000 followers at the end of the year. Follow us on LinkedIn.
*
Building on this momentum, we’re ready to rock into 2026. Guided by our core values—curiosity, fun, and quality— we hope to keep exploring, enjoying and delivering work we’re proud of.